BMO Capital analyst Kostas Biliouris downgraded Tourmaline Bio (TRML) to Market Perform from Outperform with a price target of $48, up from $35, after the company agreed to be acquired by Novartis (NVS) for $48 per share or $1.4B. BMO expects a “smooth” deal closure by Q4 without material antitrust concerns.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML: